Form 4: Abbott Laboratories Director Daniel J. Starks Reports Acquisition of Common Shares and Stock Options

Director Daniel J. Starks reports acquisition of Abbott Laboratories common shares and stock options through incentive programs and a trust.

Summary

• Daniel J. Starks, a director of Abbott Laboratories, reported transactions involving the company's securities on April 25, 2025.
• Starks acquired 1,635 common shares through restricted stock units under the Abbott Laboratories 2017 Incentive Stock Program.
• These restricted stock units will be paid in Abbott common shares upon separation from service, death, or a change in control.
• Starks also acquired 4,516 stock options under the same incentive program, exercisable from April 25, 2025, to April 24, 2035, at a price of $128.4.
• Additionally, 258 common shares are held indirectly through the Alynne Starks 2012 Irrevocable Trust, for which Starks serves as the sole trustee.
• Following these transactions, Starks beneficially owns 6,728,817 common shares directly.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices and insider alignment with company performance.

Positives

• The acquisition of restricted stock units and stock options aligns the director's interests with the long-term performance of Abbott Laboratories.
• The incentive stock program encourages directors to remain with the company or ensure a smooth transition in the event of a change in control.

Future Outlook

The restricted stock units will be paid out in Abbott common shares upon the director's separation from service, death, or a change in control, as defined in the 2017 Incentive Stock Program.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding the director's holdings and incentives.
• Employees may view the incentive program as a positive aspect of the company's compensation structure.

Key Dates

Keywords

Abbott Laboratories, Daniel J. Starks, Form 4, Director, Common Shares, Stock Options, Incentive Stock Program, Beneficial Ownership, Restricted Stock Units